Skip to main content

Datatrak International Launches ePRO, eCOA and eConsent Solution to Support the Advancement of Decentralized Trials Globally

Written by Customer Service on . Posted in Public Companies.

CLEVELAND, OH, April 29, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Datatrak International, Inc. (OTC Markets: DTRK), a worldwide Software-as-a-Service (“SaaS”) provider and innovation leader of cloud-based technologies for the life sciences industry, is proud to announce that Datatrak Direct, an all in one iOS and Android app for ePRO, eCOA and eConsent, is now live. This innovative product is available for the data collection from patients or sites at anytime, anywhere.

Datatrak Direct is a powerful and robust tool that we believe will be pivotal in the advancement of clinical trials. Data entered from any device with Datatrak’s smart app is then stored on the Datatrak Enterprise Cloud, securing data under one platform. We believe this feature will help clients gain enhanced insight into all of their data across sites for swift and informed decisions.

“We have worked very diligently to supply the industry with products that put the power in our client’s hands,” says Niki Kutac, VP, Marketing & Product Management at Datatrak. “Datatrak continues to expand on this with the design tool feature within Datatrak Direct. Trial design is in the user’s control with drag and drop features for optimization and library capability for quick and easy set-up.”  

Datatrak is focused on bringing leading-edge technology to the forefront of the clinical trial industry. By delivering a product where teams can automate workflows and edit checks to ensure higher quality data in real-time, we believe user satisfaction and engagement will increase while decreasing the risk of human errors.

“While Datatrak has been developing a patient direct strategy for years, the need for such a solution has been greatly accelerated over the last year. With this innovative and sustainable approach to decentralized trials, Datatrak Direct provides clients with the right tools and capabilities to adapt and grow with the industry’s demands while also enhancing patient engagement and ensured accuracy,” said Scott DeMell, VP, Sales at Datatrak.

Datatrak Direct is the solution to running trials virtually and efficiently. Now available as a valued asset for your next study. To learn more about Datatrak Direct, visit our website here.

About Datatrak International, Inc.

Datatrak International, Inc. is a software-as-a-service provider of enterprise cloud-based technologies for the life sciences industry.  Datatrak’s unified eClinical solutions and related services help improve cost and time efficiencies for the clinical trials industry. Datatrak built its multi-component, comprehensive solution on a single, unified platform and expanded this concept to include services delivery via Datatrak’s Clinical and Consulting Services group. The Datatrak Enterprise Cloud software solution, deployed worldwide through an ASP or Enterprise Transfer offering, supports Preclinical and Phase I – Phase IV drug and device studies in multiple languages throughout the world. For more information, visit http://www.datatrak.com.

Scott DeMell
scott.demell@datatrak.com
440-443-0082 x158

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.